MARKET

YMTX

YMTX

Yumanity Therapeutics Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

19.61
-0.61
-3.02%
Opening 13:17 01/22 EST
OPEN
20.18
PREV CLOSE
20.22
HIGH
20.18
LOW
19.52
VOLUME
15.47K
TURNOVER
--
52 WEEK HIGH
44.00
52 WEEK LOW
16.27
MARKET CAP
197.96M
P/E (TTM)
-1.3121
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Yumanity Therapeutics to Present at the H.C. Wainwright Virtual BioConnect Conference
Yumanity Therapeutics (Nasdaq: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced that Paulash Mohsen, Chief Business Officer...
GlobeNewswire · 01/06 13:00
Yumanity Therapeutics to Present at the H.C. Wainwright Virtual BioConnect Conference
BOSTON, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (Nasdaq: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced t...
GlobeNewswire · 01/06 13:00
Anthony Coles Reports 8.2% Stake In Yumanity Therapeutics As Of Dec. 22
-SEC Filing
SEC Filing · 01/04 21:19
The Daily Biotech Pulse: FDA Nod For Amphastar's Generic Glucagon, Arcturus Sinks On Vaccine Data, Decision Day For Osmotica
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Dec. 28)
Benzinga · 12/29/2020 13:09
Yumanity Therapeutics Completes Reverse Merger with Proteostasis Therapeutics
Shares of Yumanity to commence trading on Nasdaq under new ticker symbol "YMTX" on December 23, 2020
GlobeNewswire · 12/23/2020 17:43
Proteostasis Therapeutics completes merger with Yumanity Therapeutics, effects 1-for-20 reverse stock split
Proteostasis Therapeutics ([[PTI]]) and Yumanity Therapeutics have completed its reverse merger.The combined company will operate under the name Yumanity Therapeutics and its shares will commence trading on the Nasdaq Capital Market on December 23,
Seekingalpha · 12/23/2020 15:11
Proteostasis Therapeutics Stockholders Approve Business Combination With Yumanity Therapeutics; Board Sets Reverse Stock Split Ratio Of 1-For-20; Sets Reverse Split Date For Today At 12 p.m. EST
Proteostasis Therapeutics, Inc. Stockholders Approve Business Combination with Yumanity Therapeutics, Inc.; Board Sets Reverse Stock Split Ratio BOSTON, Dec. 22, 2020 /PRNewswire/ -- Proteostasis
Benzinga · 12/22/2020 15:53
Proteostasis Therapeutics, Inc. Stockholders Approve Business Combination with Yumanity Therapeutics, Inc.; Board Sets Reverse Stock Split Ratio
, /PRNewswire/ -- Proteostasis Therapeutics, Inc. ("Proteostasis") (Nasdaq: PTI) announced today that, based on the final vote count certified by the inspector of elections at its reconvened special meeting of stockholders held at on (the "Special Meeting"), its stockholders approved all of the proposals related to the merger (the "Merger") as contemplated by the Agreement and Plan of Merger and Reorganization, dated , as amended, by and among Proteostasis, Yumanity Holdings, LLC ("Holdings"), Yumanity Therapeutics, Inc. ("Yumanity"), a wholly-owned subsidiary of Holdings, and Pangolin Merger Sub, a wholly-owned subsidiary of Proteostasis ("Merger Sub") (the "Merger Agreement"), including (i) the issuance of Proteostasis common stock in the Merger in accordance with the terms of the Merger Agreement; (ii) a reverse stock split of Proteostasis common stock, at a ratio of one new share for every 20 to 30 shares outstanding, with the exact ratio and effective time of the reverse stock split to be determined by the Proteostasis board of directors and publicly announced by press release; and (iii) an amendment to the Proteostasis certificate of incorporation to effect the change of name from "Proteostasis Therapeutics, Inc." to "Yumanity Therapeutics, Inc." Also approved was the compensation that will or may become payable by Proteostasis to its named executive officers in connection with the Merger, on a non-binding advisory vote basis.
PR Newswire - PRF · 12/22/2020 15:48
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of YMTX. Analyze the recent business situations of Yumanity Therapeutics Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average YMTX stock price target is 98.00 with a high estimate of 160.00 and a low estimate of 36.00.
EPS
Institutional Holdings
Institutions: 92
Institutional Holdings: 20.60M
% Owned: 204.02%
Shares Outstanding: 10.09M
TypeInstitutionsShares
Increased
8
36.46K
New
19
119.64K
Decreased
14
25.14K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.59%
Pharmaceuticals & Medical Research
+0.70%
Key Executives
Chairman/Executive Board
N. Anthony Coles
President/Chief Executive Officer/Director
Richard Peters
Chief Financial Officer
Paulash Mohsen
Chief Accounting Officer
Marie Epstein
Chief Scientific Officer
Benito Munoz
Other
Geoffrey Gilmartin
Director
Patricia Allen
Director
Richard Heyman
Director
Cecil Pickett
Director
Lynne Zydowsky
Independent Director
David Arkowitz
Independent Director
Kimberlee Drapkin
Independent Director
Jeffery Kelly
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About YMTX
Yumanity Therapeutics Inc, formerly Proteostasis Therapeutics, Inc., is a clinical-stage biopharmaceutical company. The Company is engaged in treatment of neurodegenerative diseases through its scientific foundation and drug discovery platform. The platform is designed to enable the Company to screen for potential disease-modifying therapies by overcoming toxicity of misfolded proteins in neurogenerative diseases. The Company's product candidate, YTX-7739, is in Phase 1 clinical development for Parkinson's disease and YTX-9184, in IND-enabling studies for Dementia with Lewy Bodies. The Company’s pipeline consists of additional programs focused on multi- system atrophy, amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease), frontotemporal lobar dementia (FTLD), and Alzheimer's disease.
More

Webull offers kinds of Yumanity Therapeutics Inc stock information, including NASDAQ:YMTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, YMTX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading YMTX stock methods without spending real money on the virtual paper trading platform.